FIELD: biotechnology.
SUBSTANCE: invention relates to chimeric antigen receptors specific for mucin-1, and can be used in medicine for the treatment of cancer. Designs of polypeptides that bind to mucin-1 and include a pair of variable heavy chain region (VH) and variable region light chain (VL) with certain combinations of CDRs have been proposed. The proposed polypeptides can be produced recombinantly and can be incorporated into a chimeric antigen receptor expressed on an immune cell for the treatment of cancer.
EFFECT: invention makes it possible to continuously provide a strong antitumor effect on various types of cancer due to the activation of the immune system in the body.
25 cl, 19 dwg, 6 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| FUSION POLYPEPTIDE CONTAINING GDF15 AND POLYPEPTIDE REGION CAPABLE OF O-GLYCOSYLATION | 2020 |
|
RU2812049C1 |
| HLA-DR-BINDING CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELL | 2019 |
|
RU2778890C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| FUSION POLYPEPTIDE INCLUDING Fc REGION OF IMMUNOGLOBULIN AND GDF15 | 2020 |
|
RU2797520C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
